Form D · Biotechnology
Jecure Therapeutics, Inc.
San Diego, CA · CIK 0001698655
Offering snapshot reported Jul 16, 2018 · SEC filing
- Reported sold
- $3M Offering amount: $3M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 9, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 16, 2018 | Initial | $3,000,000 | No comparison | 4 | SEC filing |
| Dec 20, 2017 | Amendment | $15,023,493 | $5,000,000vs Feb 22, 2017 | 4 | SEC filing |
| Feb 22, 2017 | Initial | $10,023,493 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-316893
Source: Form D, filed Jul 16, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Bradley Bolzon, Ph.D. | Director |
| Ariel Feldstein, M.D. | Director |
| Jeffrey Stafford, Ph.D. | Director, Executive |
| James Veal, Ph.D. | Executive |
| Thomas Woiwode, Ph.D. | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
4757 Nexus Center Drive, Suite 150
San Diego, CA, 92121
San Diego, CA, 92121